Postdoctoral Positions in Precision Oncology Science:
The Kuhn and Hicks Laboratory at the USC Michelson Center for Convergent Bioscience is looking for three postdoctoral fellows to focus on specific single cell and liquid biopsy projects in breast, lung and prostate cancer. Critical to being a successful candidate are the determination to improving outcomes for cancer patients through scientific discovery and the application of computational and analytical skills to complex data sets.
Breast Cancer Focus: Understanding the temporal evolution of breast cancer under therapeutic pressure using a multimodal liquid biopsy approach.
Lung Cancer Focus: Earlier diagnosis to improve outcomes for lung cancer patients using an integration of clinical and liquid biopsy data.
Prostate Cancer Focus: Stratification of early stage/organ confined prostate cancer patients using single cell science.
29 Dec /By kuhnadmin/0 Comments/Kuhn News, News Article Postdoctoral Positions in Precision Oncology Science The Kuhn and Hicks Laboratory at the USC Michelson Center for Convergent Bioscience (Los Angeles, CA) is looking for three postdoctoral fellows to focus on specific single cell and liquid bio...
Check out Dr. Peter Kuhn’s takeover of The Breast Cancer Research Foundation’s Instagram account! Here's one of his posts explaining why he's invested in breast cancer research:
“People often ask me why I am so deeply vested in breast cancer research. To answer that question, I look no further than my mom. She is a thirty-year breast cancer survivor who just celebrated her 80th birthday. Here she is with my two children. My mom was treated on an early clinical trial using radiation therapy. Through her experience, I learned that pain is often the first sign of metastatic disease. This always seemed ‘insane’ or maybe ‘ridiculous’ to me since it was an indication that somewhere in the body about a billion cancer cells had the opportunity to grow uncontrollably. My goal is to change that. While tremendous advancements have been made since her diagnosis, I hope outcomes from my research will ensure more women and men impacted by breast cancer will follow in her footsteps. Thank you everyone for following and to BCRF, @autonation and @curebowl whose support allows my team and I to accomplish our goal of advancing precision medicine to save more lives. Don’t forget to tune in to the AutoNation Cure Bowl game on 12/16 at 2:30PM EST on @CBSSports! Together we will #BeTheEnd of breast cancer.”
Watch as experts discuss the connection between diversity and cancer research to enable personalized cancer treatment.
USC researchers Peter Kuhn, of the USC Michelson Center for Convergent Bioscience, and John Carpten, of Keck Medicine of USC's Institute of Translational Genomics, share their thoughts.
The work entitled “Multiplex protein detection on circulating tumor cells from liquid biopsies using imaging mass cytometry” by E. Gerdtsson and colleagues is now published in Convergent Science Physical Oncology. Congratulations to the authors!
In this work the authors describe the integration of imaging mass cytometry (IMC) using metal-labeled antibodies as implemented on the Fluidigm Hyperion Imaging System into the workflow of the previously established High-Definition Single Cell Analysis (HD-SCA) assay for liquid biopsies, along with methods for image analysis and signal normalization. Using liquid biopsies from a metastatic prostate cancer case, they demonstrate that IMC can extend the reach of CTC characterization to include dozens of protein biomarkers, with the potential to understand a range of biological properties that could affect therapeutic response, metastasis and immune surveillance when coupled with simultaneous phenotyping of thousands of leukocytes.
Erik Gerdtsson1, Milind Pore2, Jana-Aletta Thiele3, Anna Sandstrom Gerdtsson4, Paymaneh Daisy Malihi5, Rafael Nevarez6, Anand Kolatkar7, Carmen Ruiz Velasco8, Sophia Wix9, Mohan Singh10, Anders Carlsson11, Amado J Zurita12, Christopher Logothetis13, Akil Merchant14, James B Hicks15 and Peter Kuhn16
The work entitled “Clonal diversity revealed by morphoproteomic and copy number profiles of single prostate cancer cells at diagnosis” by PD Malihi and colleagues is now published in Convergent Science Physical Oncology. Congratulations to the authors!
In this work the authors characterized the molecular heterogeneity associated with de novo metastatic prostate cancer (PCa) using the multiplatform single cell profiling enabled by the High-Definition Single Cell Analysis (HD-SCA). The analysis of single cells revealed several clonal origins of metastatic PCa in a newly diagnosed, untreated patient with polymetastatic disease. This case demonstrated that real-time molecular profiling of cells collected through prostate and bone marrow biopsies is feasible and has the potential to elucidate the origin and evolution of metastatic tumor cells. These findings indicate that biological and genomic data obtained through longitudinal biopsies can be used to reveal the properties of PCa and can impact clinical management.
Paymaneh Daisy Malihi1, Michael Morikado2, Lisa Welter3, Sandy T Liu4, Eric T Miller5, Radu M Cadaneanu6, Beatrice Knudsen7, Michael S Lewis8, Anders Carlsson9, Carmen Ruiz Velasco10, Anand Kolatkar11, Mariam Rodriguez-Lee12, Isla Garraway13, James B Hicks14 and Peter Kuhn15